GO:0032036 myosin heavy chain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032036 (myosin heavy chain binding) is a molecular function defined as binding to a heavy chain of a myosin complex.
• Myosin heavy chains are the force-generating subunits of myosin motors, and their binding partners regulate assembly, localization, and activity in striated and non-muscle cells.
• Mutations in myosin heavy chain genes such as MYH7 and MYH9 cause hypertrophic cardiomyopathy, skeletal myopathies, and blood disorders, making this binding function clinically important [1,3,6].
• The term is studied using knockout, point-mutation, knock-in, and overexpression cell models combined with binding assays, imaging, and proteomics [4,5,7].
• CRISPR-based editing enables precise dissection of myosin heavy chain binding interfaces and their downstream effects [4,5].
• Understanding GO:0032036 supports drug target discovery in cardiomyopathy, thrombocytopenia, and infectious disease [1,4,5].
Description
GO:0032036, myosin heavy chain binding, is a molecular function term in the Gene Ontology that describes the selective interaction of a protein with the heavy chain subunit of a myosin complex. Myosin heavy chains are the motor subunits that convert chemical energy into mechanical force, and proteins that bind them can influence filament assembly, motor activity, and cellular localization. Because myosin heavy chains participate in muscle contraction, cytokinesis, and intracellular transport, their binding partners are central to both normal physiology and disease [2,6]. Researchers study this term to understand how myosin complexes are assembled and regulated, and to identify therapeutic targets in cardiomyopathy, myopathies, and immune disorders [1,3,6]. The function is experimentally tractable: binding can be assayed biochemically, visualized by imaging, and genetically dissected using CRISPR models [4,5,7].
myosin heavy chain binding At A Glance
| GO ID | GO:0032036 |
|---|---|
| GO term | myosin heavy chain binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a heavy chain of a myosin complex. |
| Major function | Mediates physical interaction with myosin heavy chain subunits, influencing myosin assembly, localization, and activity. |
| Example binding partners | MYH7, MYH9, and other myosin heavy chain isoforms [1,4,5]. |
| Disease relevance | Hypertrophic cardiomyopathy, skeletal myopathies, immune thrombocytopenia, and viral entry [1,3,4,5,6]. |
| Research methods | Co-immunoprecipitation, pull-down assays, FRET, CRISPR knockout/knock-in, and proteomics [4,5,7]. |
What Is GO:0032036?
In plain terms, GO:0032036 describes the ability of a protein to physically attach to the heavy chain of a myosin molecule. The QuickGO definition states: Binding to a heavy chain of a myosin complex. This is a molecular function, meaning it describes what a gene product does at the molecular level rather than a whole pathway or cellular structure. The interaction may be direct or part of a larger assembly, and it is distinct from binding to myosin light chains or to actin. Proteins annotated with this function often act as chaperones, assembly factors, or regulatory subunits that determine when and where myosin heavy chains function [2,7].
Why Is myosin heavy chain binding Important in Cell Biology?
GO:0032036 matters because myosin heavy chains are essential force-generating proteins, and the proteins that bind them control when, where, and how myosin functions. Disrupting these interactions can cause or modify human disease, including hypertrophic cardiomyopathy, skeletal myopathies, and blood disorders [1,3,6]. In addition, myosin heavy chain binding can be exploited by pathogens, as shown for Japanese encephalitis virus entry. Thus, this molecular function sits at the intersection of muscle biology, cell motility, immunity, and infection, making it a high-value target for mechanistic and translational research [2,4,5].
• Mutations in myosin heavy chain genes are a leading cause of hypertrophic cardiomyopathy [1,3].
• Myosin heavy chain binding regulates striated muscle resting state and contractility.
• Defects in myosin heavy chain interactions cause skeletal myopathies.
• MYH9 binding by YAP1 influences thrombopoiesis in immune thrombocytopenia.
• Myosin heavy chain 9 acts as a host factor for Japanese encephalitis virus entry.
• Phosphorylation of the myosin heavy chain regulates assembly and binding partner affinity.
• The function is druggable: small molecules can modulate myosin activity and interactions.
• CRISPR screens can identify novel myosin heavy chain binding proteins [4,5].
• Understanding this term aids diagnosis of inherited cardiomyopathies [1,3].
• It provides a model for studying mechanotransduction and cell shape control [2,7].
Molecular Mechanism of myosin heavy chain binding
Recognition of the myosin heavy chain surface
In simple terms: A binding protein finds a specific patch on the myosin heavy chain and attaches to it.
Myosin heavy chains present distinct surface regions that are recognized by partner proteins. For example, the N-terminal region of MYH9 is bound by YAP1, and this interaction is required for thrombopoiesis. Similarly, viral proteins can engage myosin heavy chains to facilitate entry. The specificity of these interactions depends on the amino acid sequence and post-translational modifications of the heavy chain.
Conformational changes and regulation by phosphorylation
In simple terms: Adding a phosphate tag to the myosin heavy chain can change its shape and how tightly it binds partners.
Phosphorylation of the myosin-IIA heavy chain regulates its assembly and the binding of partners such as Mts1. This modification can switch the heavy chain between folded and extended conformations, thereby controlling access to binding sites. Such regulation is critical for dynamic processes like cytokinesis and cell migration.
Assembly into myosin complexes
In simple terms: Binding partners help myosin heavy chains come together into functional motors.
Myosin heavy chains must dimerize and assemble into filaments to generate force. Binding proteins can act as chaperones or assembly factors that promote proper folding and oligomerization. In striated muscle, the resting state is modulated by interactions with myosin heavy chain binding proteins, which affect contractile readiness.
Functional consequences in cells
In simple terms: Once bound, the partner can change what the myosin motor does in the cell.
Binding to myosin heavy chains can alter motor activity, cargo binding, or localization. For instance, YAP1 binding to MYH9 links myosin function to transcriptional regulation and platelet production. In muscle, mutations that disrupt these interactions lead to hypercontractility or weakness, as seen in hypertrophic cardiomyopathy and myopathies [1,6].
Key Genes Involved in GO:0032036 myosin heavy chain binding
The following genes encode myosin heavy chains or their binding partners that are directly relevant to GO:0032036.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYH7 | Beta-myosin heavy chain in cardiac and skeletal muscle | Mutations cause hypertrophic cardiomyopathy and myopathies [1,3,6] |
| MYH6 | Alpha-myosin heavy chain in atrial muscle | Cardiac contractility and disease modeling |
| MYH9 | Non-muscle myosin heavy chain IIA | Host factor for JEV, YAP1 binding in thrombopoiesis [4,5] |
| MYH2 | Fast skeletal muscle myosin heavy chain | Skeletal myopathies |
| MYH3 | Embryonic skeletal muscle myosin | Developmental muscle disorders |
| MYH8 | Perinatal skeletal muscle myosin | Congenital myopathies |
| MYH1 | Adult fast skeletal muscle myosin | Muscle physiology |
| MYH4 | Fast glycolytic skeletal muscle myosin | Muscle fiber type studies |
| MYH10 | Non-muscle myosin heavy chain IIB | Cell motility and cytokinesis |
| MYH11 | Smooth muscle myosin heavy chain | Vascular and visceral smooth muscle function |
| MYH14 | Non-muscle myosin heavy chain IIC | Hearing and cell polarity |
| YAP1 | Transcriptional co-activator binding MYH9 | Thrombopoiesis and immune thrombocytopenia |
| Mts1 | S100A4, binds myosin-IIA heavy chain | Regulates assembly and metastasis |
| MYL2 | Myosin regulatory light chain | Modulates heavy chain function |
| MYL3 | Myosin essential light chain | Modulates heavy chain function |
| TTN | Titin, binds myosin heavy chain in sarcomeres | Cardiomyopathy and muscle elasticity |
| ACTN2 | Alpha-actinin-2, interacts with myosin complex | Z-disc and cardiomyopathy |
How Is myosin heavy chain binding Regulated?
The binding of proteins to myosin heavy chains is regulated at multiple levels. Phosphorylation of the myosin heavy chain itself can alter its assembly state and partner affinity, as shown for myosin-IIA. In striated muscle, the resting state is modulated by interactions with myosin heavy chain binding proteins, which can be influenced by calcium and regulatory light chains. Additionally, transcriptional regulation of myosin heavy chain genes, such as MYH7 and MYH6, affects the availability of binding sites. Viral proteins can also hijack these interactions, as seen for MYH9 in Japanese encephalitis virus entry. Thus, regulation occurs through post-translational modifications, conformational changes, and expression levels of both the heavy chain and its partners.
myosin heavy chain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYH7 | Hypertrophic cardiomyopathy | Knock-in mouse or iPSC-derived cardiomyocytes with patient mutations [1,3] |
| MYH9 | Immune thrombocytopenia; JEV entry | Knockout megakaryocytes or U251 cells [4,5] |
| MYH2 | Skeletal myopathy | Knockout or point-mutation C2C12 myotubes |
| YAP1 | Thrombopoiesis | Knockout or overexpression in megakaryocytes |
| Mts1 (S100A4) | Metastasis; myosin-IIA assembly | Overexpression in cancer cell lines |
Hypertrophic cardiomyopathy and myosin heavy chain mutations
Mutations in MYH7, encoding beta-myosin heavy chain, are among the most common causes of hypertrophic cardiomyopathy [1,3]. These mutations can disrupt interactions with binding partners such as titin or myosin light chains, leading to hypercontractility and sarcomere dysfunction. Genetic testing for MYH7 mutations is a standard part of cardiomyopathy diagnosis.
Skeletal myopathies associated with myosin heavy chain defects
Mutations in skeletal muscle myosin heavy chain genes, including MYH2, MYH3, and MYH8, cause congenital and distal myopathies. These mutations often affect the motor domain or binding interfaces, impairing force generation and assembly.
MYH9-related disorders and immune thrombocytopenia
MYH9 is a non-muscle myosin heavy chain that binds YAP1 to regulate thrombopoiesis; disruption of this interaction contributes to immune thrombocytopenia. MYH9 also serves as a host factor for Japanese encephalitis virus entry, linking myosin heavy chain binding to infectious disease.
Myosin heavy chain binding in osteoarthritis and other conditions
Although not directly a myosin heavy chain binding protein, DPP4 exacerbates osteoarthritis in an enzyme-independent manner, highlighting the broader relevance of protein-protein interactions in joint disease. This suggests that myosin heavy chain binding partners could be explored in musculoskeletal research.
From myosin heavy chain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate binding protein affect myosin heavy chain function? | CRISPR knockout in HEK293 or C2C12 cells [4,5] |
| Does a specific point mutation in MYH7 alter binding affinity? | Point-mutation knock-in in iPSCs or mouse [1,3] |
| Can a binding interface be tagged for live imaging? | Tagged knock-in of MYH9 or partner |
| Does overexpression of a binding partner drive disease phenotypes? | Overexpression in cardiomyocytes or megakaryocytes [4,7] |
| Which proteins bind myosin heavy chains in a disease context? | Proteomics and CRISPR library screening [4,5] |
| Does viral entry require myosin heavy chain binding? | Knockout of MYH9 in susceptible cells |
How to Study the myosin heavy chain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between proteins | Confirm myosin heavy chain binding |
| GST pull-down | Direct binding in vitro | Map binding domains |
| FRET/PLA | Proximity in live cells | Visualize interactions |
| CRISPR knockout screen | Genes required for a phenotype | Identify host factors for viral entry |
| Phospho-specific antibodies | Phosphorylation state of myosin heavy chain | Study regulation of assembly |
| Live-cell imaging | Localization and dynamics | Track myosin assembly |
| Proteomics (AP-MS) | Protein complex composition | Discover new binding partners |
| Contractility assays | Force generation | Assess functional impact of mutations |
Binding assays (co-IP, pull-down, FRET)
Co-immunoprecipitation and GST pull-down are standard for detecting myosin heavy chain binding [4,7]. FRET and proximity ligation can visualize interactions in live cells.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes required for myosin heavy chain binding or downstream phenotypes, as demonstrated for MYH9 in viral entry.
Imaging and proteomics
Fluorescence microscopy of tagged myosin heavy chains reveals localization and assembly. Mass spectrometry of myosin complexes identifies novel binding partners.
Functional assays in muscle and non-muscle cells
Contractility assays in cardiomyocytes and platelet production assays in megakaryocytes link binding to physiology [1,4]. Myopathy models use muscle cell differentiation and force measurements.
How CRISPR Can Be Used to Study GO:0032036 myosin heavy chain binding
Knockout
CRISPR knockout of myosin heavy chain genes or their binding partners can reveal loss-of-function phenotypes. For example, MYH9 knockout reduces Japanese encephalitis virus entry, confirming its role as a host factor. Knockout of YAP1 or MYH9 in megakaryocytes impairs thrombopoiesis.
Point Mutation
Introducing disease-associated point mutations into MYH7 or MYH9 via CRISPR allows precise testing of binding affinity and function. Such models mimic human cardiomyopathy mutations [1,3].
Knock-in
Tagged knock-in of myosin heavy chains (e.g., GFP or HaloTag) enables live-cell imaging of assembly and binding dynamics. Knock-in of patient mutations in iPSCs provides isogenic disease models.
Overexpression
Overexpression of binding partners such as Mts1 or YAP1 can drive pathological phenotypes, including altered myosin assembly and metastasis [4,7]. Overexpression in cell lines is useful for gain-of-function studies.
How EDITGENE Supports myosin heavy chain binding Research
Researchers studying myosin heavy chain binding-related genes often need to determine whether a candidate gene is causally involved in myosin assembly, localization, or disease. EDITGENE provides end-to-end CRISPR services to create precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for myosin heavy chain binding research.
Frequently Asked Questions About myosin heavy chain binding
What is GO:0032036?
GO:0032036 is the Gene Ontology molecular function term for myosin heavy chain binding, defined as binding to a heavy chain of a myosin complex.
What genes are involved in myosin heavy chain binding?
Key genes include MYH7, MYH9, MYH2, MYH6, and binding partners such as YAP1 and Mts1 [1,4,5,7].
What diseases are associated with myosin heavy chain binding?
Hypertrophic cardiomyopathy, skeletal myopathies, immune thrombocytopenia, and viral infections like Japanese encephalitis [1,3,4,5,6].
How is myosin heavy chain binding regulated?
It is regulated by phosphorylation of the heavy chain, conformational changes, and expression levels of binding partners [2,7].
What methods study myosin heavy chain binding?
Co-immunoprecipitation, pull-down, FRET, CRISPR screens, and proteomics [4,5,7].
Why is MYH7 important in cardiomyopathy?
MYH7 mutations are a leading cause of hypertrophic cardiomyopathy and affect sarcomere function [1,3].
What is the role of MYH9 in immune thrombocytopenia?
YAP1 binds MYH9 to regulate thrombopoiesis, and disruption contributes to immune thrombocytopenia.
Can viruses use myosin heavy chain binding?
Yes, Japanese encephalitis virus requires MYH9 for entry and replication.
What CRISPR models are used for myosin heavy chain binding?
Knockout, point mutation, knock-in, and overexpression models in cell lines and iPSCs [4,5].
How can EDITGENE help study myosin heavy chain binding?
EDITGENE provides custom CRISPR knockout, point mutation, knock-in, overexpression, and library screening services.
Conclusion
GO:0032036 myosin heavy chain binding is a fundamental molecular function that governs myosin assembly, activity, and cellular roles. Its importance spans muscle physiology, blood disorders, and infectious disease, with MYH7 and MYH9 as prominent examples [1,4,5]. Continued research using CRISPR models and biochemical assays will uncover new binding partners and therapeutic opportunities. EDITGENE offers comprehensive services to accelerate these discoveries.
References
- 1. Marian AJ. 2021. Molecular Genetic Basis of Hypertrophic Cardiomyopathy.. Circ Res 128(10):1533-1553 PMID: 33983830
- 2. Lewis CTA et al.. 2023. Myosin Heavy Chain as a Novel Key Modulator of Striated Muscle Resting State.. Physiology (Bethesda) 38(1):0 PMID: 36067133
- 3. Richard P et al.. 2003. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.. Circulation 107(17):2227-32 PMID: 12707239
- 4. Hu S et al.. 2024. YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia.. Blood 144(20):2136-2148 PMID: 39190466
- 5. Xu K et al.. 2025. Myosin heavy chain 9 is a critical host factor for Japanese encephalitis virus entry and replication in U251 cells.. Vet Microbiol 310:110723 PMID: 40939426
- 6. Oldfors A et al.. 2004. Myopathies associated with myosin heavy chain mutations.. Acta Myol 23(2):90-6 PMID: 15605950
- 7. Dulyaninova NG et al.. 2005. Regulation of myosin-IIA assembly and Mts1 binding by heavy chain phosphorylation.. Biochemistry 44(18):6867-76 PMID: 15865432
- 8. Li X et al.. 2025. Dipeptidyl Peptidase 4 (DPP4) Exacerbates Osteoarthritis Progression in an Enzyme-Independent Manner.. Adv Sci (Weinh) 12(6):e2410525 PMID: 39680708
